Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiotech Gwth Regulatory News (BIOG)

Share Price Information for Biotech Gwth (BIOG)

Share Price is delayed by 15 minutes
Get Live Data
1,232.00    -30.00 (-2.38%)
Bid:
1,232.00
Ask:
1,246.00
Spread: 14.00 (1.136%)
Market Cap: £239.12m
BIOG Live PriceLast checked at - London Stock Exchange

Intraday Biotech Gwth Share Chart

Result of AGM

18 Jul 2024 16:48

The Biotech Growth Trust PLC - Result of AGM

The Biotech Growth Trust PLC - Result of AGM

PR Newswire

LONDON, United Kingdom, July 18

THE BIOTECH GROWTH TRUST PLC

(the "Company")

 

Results of the Annual General Meeting

 

The Board is pleased to announce that at the Annual General Meeting (AGM) of the Company held on Thursday, 18 July 2024 all resolutions as detailed below were duly passed by shareholders on a poll.

 

Resolutions

Votes For

%

Votes Against

%

Total Votes Cast

Votes

Withheld*

 

1. To receive the audited financial statements and the Report of the Directors for the year ended 31 March 2024.

 

9,341,023

99.97

2,814

0.03

9,343,837

1,848

2. To approve the Directors' Remuneration Report for the year ended 31 March 2024.

 

9,297,309

99.58

39,122

0.42

9,336,431

9,254

3. To elect Hamish Baillie as a Director of the Company.

 

9,326,509

99.85

14,088

0.15

9,340,597

5,088

4. To re-elect Geoff Hsu as a Director of the Company.

 

9,324,487

99.83

16,110

0.17

9,340,597

5,088

5. To re-elect Julia Le Blan as a Director of the Company.

 

9,092,656

97.35

247,840

2.65

9,340,496

5,188

6. To re-elect Dr Nicki Shepherd as a Director of the Company.

 

9,096,040

97.38

244,456

2.62

9,340,496

5,188

7. To re-elect The Rt Hon Lord Willetts as a Director of the Company.

 

9,049,367

96.89

290,754

3.11

9,340,121

5,563

8. To re-elect Roger Yates as a Director of the Company.

 

8,825,220

94.48

515,276

5.52

9,340,496

5,188

9. To re-appoint BDO LLP as auditor and to authorise the Audit Committee to determine their remuneration.

 

8,257,243

99.88

9,687

0.12

8,266,930

1,078,755

10. To authorise the Directors to allot securities in the Company.

 

9,321,581

99.79

19,686

0.21

9,341,267

4,418

11#. To disapply the rights of pre-emption in relation to the allotment of securities.

 

9,306,351

99.62

35,636

0.38

9,341,987

3,698

12#. To authorise the Company to make market purchases of Ordinary shares in the Company.

 

9,333,066

99.93

6,671

0.07

9,339,737

5,948

13#. That the Directors be permitted to hold General Meetings (excluding the AGM) on not less than 14 clear days' notice.

 

9,311,567

99.66

31,809

0.34

9,343,376

2,309

 

# - Special Resolution

 

* Please note that a `vote withheld' is not a vote in law and is not counted in the calculation of the proportion of votes `For' and `Against' a resolution.

 

Any proxy votes which are at the discretion of the Chairman have been included in the "For" total.

 

At the date of the AGM, the total number of Ordinary shares of 25p each in issue and the total number of voting rights was 32,887,198.

 

The proxy voting figures will shortly also be available on the Company's website at www.biotechgt.com

In accordance with Listing Rule 9.6.2, the full text of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Resolutions 10 to 13 will additionally be filed at Companies House.

 

18 July 2024

 

For further information please contact:

 

Katherine Manson

Frostrow Capital LLP - Company Secretary

020 3709 8734

 



Date   Source Headline
29th Dec 20251:56 pmPRNNet Asset Value(s)
24th Dec 202511:38 amPRNNet Asset Value(s)
23rd Dec 20255:13 pmRNSTransaction in Own Shares
23rd Dec 20255:13 pmPRNTransaction in Own Shares
23rd Dec 202512:07 pmPRNNet Asset Value(s)
22nd Dec 202512:55 pmRNSBioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics
22nd Dec 202512:55 pmPRNBioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics
22nd Dec 202512:26 pmPRNNet Asset Value(s)
19th Dec 20255:27 pmRNSTransaction in Own Shares
19th Dec 20255:27 pmPRNTransaction in Own Shares
19th Dec 20251:46 pmPRNNet Asset Value(s)
18th Dec 20254:00 pmPRNNet Asset Value(s)
17th Dec 20252:00 pmPRNNet Asset Value(s)
16th Dec 202512:41 pmPRNNet Asset Value(s)
15th Dec 20251:59 pmPRNNet Asset Value(s)
12th Dec 20255:33 pmPRNTransaction in Own Shares
12th Dec 20252:24 pmPRNMonthly Fact Sheet as at 30 November 2025
12th Dec 20252:20 pmPRNNet Asset Value(s)
11th Dec 20251:58 pmPRNNet Asset Value(s)
10th Dec 202512:56 pmPRNNet Asset Value(s)
9th Dec 20251:21 pmPRNNet Asset Value(s)
8th Dec 20251:24 pmPRNNet Asset Value(s)
5th Dec 20255:18 pmPRNTransaction in Own Shares
5th Dec 20252:24 pmPRNNet Asset Value(s)
4th Dec 20251:28 pmPRNNet Asset Value(s)
3rd Dec 20253:46 pmPRNNet Asset Value(s)
2nd Dec 20253:31 pmPRNDirector Declaration
2nd Dec 20251:24 pmPRNNet Asset Value(s)
1st Dec 20252:36 pmPRNNet Asset Value(s)
1st Dec 20259:47 amPRNTotal Voting Rights
28th Nov 20255:17 pmPRNTransaction in Own Shares
28th Nov 20251:11 pmPRNNet Asset Value(s)
27th Nov 20251:34 pmPRNNet Asset Value(s)
26th Nov 20253:23 pmPRNNet Asset Value(s)
25th Nov 20251:03 pmPRNNet Asset Value(s)
24th Nov 20251:16 pmPRNNet Asset Value(s)
21st Nov 20255:07 pmPRNTransaction in Own Shares
21st Nov 202512:27 pmPRNNet Asset Value(s)
20th Nov 20251:07 pmPRNNet Asset Value(s)
20th Nov 20257:00 amPRNHalf-year Financial Report
19th Nov 20251:55 pmPRNNet Asset Value(s)
18th Nov 20251:08 pmPRNNet Asset Value(s)
17th Nov 20251:51 pmPRNNet Asset Value(s)
14th Nov 20255:17 pmPRNTransaction in Own Shares
14th Nov 202512:00 pmPRNNet Asset Value(s)
13th Nov 20252:18 pmPRNNet Asset Value(s)
12th Nov 20254:37 pmPRNResult of General Meeting
12th Nov 20251:10 pmPRNNet Asset Value(s)
12th Nov 202511:13 amPRNMonthly Fact Sheet as at 31 October 2025
11th Nov 20251:22 pmPRNNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.